A study conducted by the Texas A&M Health Institute of Biosciences and Technology reveals a connection: the potential of bromodomain and extraterminal domain (BET) inhibitors in not only reducing the risk of colorectal cancer but also battling the COVID-19 virus. Read more about it at:
https://vitalrecord.tamhsc.edu/colorectal-cancer-and-covid-19-inhibitors-to-combat-both/